(Q39592865)

13 September 2017

1 reference

title

Human interleukin 2: molecular biology, physiology and clinical possibilities (English)

1 reference

13 September 2017

0 references

0 references

Mertelsmann R

1 reference

13 September 2017

Welte K

series ordinal

1 reference

13 September 2017

publication date

1 September 1986

1 reference

13 September 2017

1 reference

13 September 2017

volume

172

1 reference

13 September 2017

issue

3-5

1 reference

13 September 2017

page(s)

400-419

1 reference

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Human interleukin 2: biochemistry, physiology, and possible pathogenetic role in immunodeficiency syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Purification and partial sequence analysis of human T-cell growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Molecular cloning of human interleukin 2 cDNA and its expression inE. coli

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Heterogeneity of human T-cell growth factor(s) due to variable glycosylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Structure of the human interleukin 2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

T-cell growth factor: complete nucleotide sequence and organization of the gene in normal and malignant cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Gene for T-Cell Growth Factor: Location on Human Chromosome 4q and Feline Chromosome B1

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Human interleukin 2 gene is located on chromosome 4

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

T cell growth factor receptors. Quantitation, specificity, and biological relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Transient expression of interleukin 2 receptors. Consequences for T cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Leukemia cell lines can replace monocytes for mitogen-induced T-lymphocyte responses: this accessory function is dependent upon their differentiation stage

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

The role of a gamma interferon-like lymphokine in the activation of T cells for expression of interleukin 2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

The mitogenic activity of OKT3 and anti-Leu 4 monoclonal antibodies: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Separation of functional subsets of human T cells by a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Purified human interleukin-2 enhances induction of immune interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Dendritic cells induce T lymphocytes to release B cell-stimulating factors by an interleukin 2-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Immunoincompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Immunocompetence and malignant lymphoma: immunologic status before therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Effects of tumor growth on interleukins and circulating immune complexes. Mechanisms of immune unresponsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Monoclonal antibody-defined T-cell phenotypes and phytohemagglutinin reactivity of E-rosette-forming circulating lymphocytes from untreated chronic myelocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

A prospective study of the changes in the immune status before, during, and after multiple-agent chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Characterization of multiple immune defects in human malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Impaired PWM-induced polyclonal B-cell activation in patients with malignancies treated with various intermittent combination chemotherapies including doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Cimetidine reduction of tumour formation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Human leukocyte interferon and cimetidine for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0171-2985%2886%2980121-8

7 January 2021

10.1016/S0171-2985(86)80121-8

Identifiers

DOI

0 references

1 reference